VBL Therapeutics to Host In-Person Key Opinion Leader Seminar on Ovarian Cancer
March 31, 2022 08:00 ET
|
VBL Therapeutics
Three leading experts in gynecological oncology will discuss treatment landscape and unmet needs in ovarian cancer Event on Monday, April 11, 2022 at 12pm EDT in New York City TEL AVIV, Israel and...
VBL Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update
March 23, 2022 07:00 ET
|
VBL Therapeutics
OVAL top-line data for ofra-vec progression free survival (PFS) primary endpoint expected in 2H 2022; with positive results, VBL anticipates submitting a Biologics License Application (BLA) in 1H 2023...
UPDATE -- VBL Therapeutics to Report Year-End 2021 Financial Results on March 23
March 14, 2022 09:57 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VLB Therapeutics to Report Year-End 2021 Financial Results on March 23
March 14, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, March 14, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company focused on developing first-in-class therapeutics for...
VBL Therapeutics Announces Completion of Enrollment in OVAL Phase 3 Registration-Enabling Trial of Ofra-Vec in Ovarian Cancer and Unanimous Recommendation by Independent Data Safety Monitoring Committee to Continue Study as Planned
March 08, 2022 08:00 ET
|
VBL Therapeutics
Phase 3 OVAL trial enrolled 409 patients globally at centers in the United States, Europe, Israel, and JapanTop-line data from progression free survival (PFS) primary endpoint expected in 2H 2022...
VBL Therapeutics to Participate at March Investor Conferences
March 03, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
February 15, 2022 16:05 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference
February 02, 2022 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for...
VBL Therapeutics Announces Appointment of Matthew Trudeau as Chief Commercial Officer
January 18, 2022 08:00 ET
|
VBL Therapeutics
CCO appointment positions VBL to advance and accelerate commercialization strategy for ofra-vec (VB-111) Enrollment in the OVAL Study, a 400 patient Phase 3 registration-enabling trial in ovarian...
VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
January 06, 2022 08:10 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat...